Spago Nanomedical: Tumorad in the spotlight
Research Update
2023-02-03
07:00
Redeye comments on Spago’s Q4 2022 report, and we estimate that the company is making solid progress towards starting its phase I/IIa trial with radionuclide drug candidate Tumorad (177Lu-SN201). Further, we judge that patient recruitment to the company’s phase IIa trial with SpagoPix (SN132D) is progressing solidly. We make some minor adjustments to our estimates and valuation.
JU
EL
Johan Unnerus
Ethel Luvall
Disclosures and disclaimers